🔎 Trials Near Me

Home › Peripheral Arterial Disease › Michigan

Peripheral Arterial Disease clinical trials in Michigan

9 studies for Peripheral Arterial Disease are looking for participants at sites in Michigan.

Cities in Michigan

EVERO Drug-coated Balloon (DCB) Randomized Trial

  • McLaren Bay Region Hospital, Bay City
Recruiting
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT07144150

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07223593

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  • Paragon Health, Inc, Kalamazoo
  • Michigan Kidney Consultants, PC, Pontiac
  • St. Clair Nephrology Research, Roseville
  • and 1 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961

Vascular Trial Associated Registry Pilot

  • Henry Ford Hospital, Detroit
  • Corewell Health West, Grand Rapids
RecruitingPhase 4
Ages 45 and older · All sexes · Updated Jul 16, 2026 · NCT07076082

The THOR IDE Study

  • Henry Ford St John Hospital, Detroit
  • Henry Ford Hospital, Detroit
Recruiting
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT05916950

Serranator POINT FORCE Registry

  • Henry Ford Health, Detroit
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT06687590

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

  • Henry Ford Health System, Detroit
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Mar 24, 2026 · NCT04774159

Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes

  • Detroit Medical Center, Detroit
RecruitingObservational study
All ages · All sexes · Updated Feb 6, 2026 · NCT01904851

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.